From CNBC:

Biotech company Viking Therapeutics is being recognized as a potential player in the weight loss drug market, valued at $100 billion by the end of the decade. Promising phase two trial results show their injection may be “best-in-class,” with potential for more entrants in the industry. Viking’s drug data surpasses competitors’. Vikings also face hurdles to entering the market and will not launch their injection until later in the decade. Despite the impressive data, it will take time for Viking’s treatment to be approved and reach the market, with more work to be done. Expectations for a partnership or takeover by a larger pharmaceutical company are high, making Viking an attractive target in the weight loss drug market. Viking’s appeal is not just limited to their injection, but their oral version as well, adding to their market potential.



Read more at CNBC: Viking Therapeutics emerges as competitor